A pharmaceutical formulations and API manufacturing company. Established in 2006, Globela is an established ISO, FDCA – India and WHO cGMP accredited formulations manufacturing company with multiple therapeutic areas including oncology, anti-infectives, gastro, CVS, etc. and sales presence across 30+ countries. It is an experienced manufacturer for high quality semi-finished, finished dosages formulation and active...Read More
Somerset Indus Capital Partners has picked up a minority stake in Gujarat-based Globela Pharma Pvt Ltd, marking the healthcare-focused private equity firm's first bet in the pharmaceutical space in India.Read More
A quick synopsis of issues and areas entrepreneurs and organizations need to keep in mind to prosper in the new, tech-enabled terrain of healthcare. Healthcare has transformed itself post-Covid. Technology has come to the fore. Remote care, wearables and digital accessories are the new norm.Read More
Earlier this month, the debut fund of healthcare-focused private equity firm Somerset Indus Capital Partners made its first partial exit via an initial public offering (IPO) from Krsnaa Diagnostics. Previously, Somerset fully exited Sandor Medicaids in 2016 via a secondary deal and partially exited Cygnus Hospitals via a strategic transaction in January 2020.Read More
Amid all the challenges, technology-enabled solutions will be key to accessible healthcare for all as it offers opportunities to streamline processing and improving overall patient experience..Read More
The current healthcare space has not seen this sort of pandemic situation before. The world has witnessed the conditions like these almost 100 years back and that leaves no traces of experience to the current generation to tackle such a situation. The main challenge all the healthcare service providers face today due to the outbreak...Read More
Somerset Indus Capital Partners proudly becomes a signatory of "Ethical Principles in Health Care" —a relevant, transparent, and accessible platform to help instill the highest ethical standards for health care delivery. Somerset believes in "Responsible Investing" and strives to create a sustainable impact in healthcare..Read More
According to a statement by the company, the funds will be used for meeting the working capital requirements and expanding the company's newly acquired In-Vitro Diagnostics segment of IRIS Healthcare.Read More
Hear Mayur Sirdesai's (Partner - Somerset Indus Capital Partners) views on investors driving healthcare innovation. Watch the episode by clicking on the link...Read More
